Archiwum zagraniczne East News 2023-12

EN_01606581_0127

30,00 EUR Private use
Making print for private purpose, storage in computer memory, no distribution rights.
40,00 EUR Internet - private use
Strictly for editorial, single use on a personal (nonprofit) web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
75,00 EUR Internet commercial use
Strictly for editorial, single use on a commercial web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
90,00 EUR Print use
Strictly for editorial, single use, inside of newspaper, magazine, book (including digital version), one edition, one single country. Not for resale.

Gross prices

special instructions

<TAB><TAB><TAB>093610+0900 JAPAN OUT

caption

A photo shows Lecanemab, sold under the brand name Leqembi, at a hospital in Itabashi Ward, Tokyo on December 25, 2023. Lecanemab is a monoclonal antibody medication used for the treatment of Alzheimer's disease. The drug was developed by Eisai and Biogen and subsequently approved in the United States and Japan.( The Yomiuri Shimbun via AP Images )

headline Archiwum zagraniczne East News 2023-12

created date 2023-12-25

credit Kota Kiriyama/Associated Press/East News

source Associated Press

byline Kota Kiriyama

original transmission reference 23359092757939

weight 5,23MB

size 42cm x 59cm by 300dpi

keywords - Show

2023, 25, A, ALZHEIMER, AND, ANTIBODY, AP, APPROVED, AT, BIOGEN, BRAND, BY, CTR, DECEMBER, DEVELOPED, DISEASE, DRUG, EISAI, FIN, FINANCE, FOR, HEALTH, HOSPITAL, HTH, IMAGES, IN, IS, ITABASHI, JAPAN, JPN, KIRIYAMA, KOTA, lecanemab, leqembi, LIF, LIFE, LIFESTYLE, MEDICATION, MEDICINE, MONOCLONAL, NAME, OF, ON, PHOTO, S, SCI, SCIENCE, SHIMBUN, SHOWS, SOLD, STATES, SUBSEQUENTLY, THE, TOKYO, TREATMENT, UNDER, UNITED, USED, VIA, WARD, WAS, YOMIURI,